Jana Fassunke

TH Köln - University of Applied Sciences — Germany

Medicine · Health Sciences

27h-index3.4kcitations114works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(72), Cancer Genomics and Diagnostics(38), Lung Cancer Diagnosis and Treatment(15), Lung Cancer Research Studies(15), Colorectal Cancer Treatments and Studies(12)

Publications114 total

Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring <i>KRAS</i> G12V mutations
Clinical Cancer Research·2025
Brief Report: MET driven resistance to sotorasib in KRAS G12C-mutant Non-small cell lung cancer and response to combined KRAS and MET inhibition
JTO Clinical and Research Reports·2025· 1 citedOpen Access
EATON: A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2025· 1 cited
1308P Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations
Annals of Oncology·2024Open Access
Molecular and clinical characteristics of patients with non-small-cell lung cancer (NSCLC) harboring <i>KRAS</i> G12V mutations.
Journal of Clinical Oncology·2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial
ESMO Open·2024· 6 citedOpen Access
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
Journal of Thoracic Oncology·2023· 17 citedOpen Access
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report
JCO Precision Oncology·2023· 3 cited
Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Data from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplemental Table 8 from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplementary Figure 1 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplement from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplement from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Data from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Sabine Merkelbach‐Bruse(39), Reinhard Büttner(26), Michaela A. Ihle(20), Carina Heydt(20), Matthias Scheffler(19), Sebastian Michels(19), Jürgen Wolf(19), Lukas C. Heukamp(14), Lucia Nogová(14), Reinhard Buettner(13), Hans‐Ulrich Schildhaus(12), Rieke Fischer(11), Anna Kron(11), Andreas H. Scheel(10), Rebecca Roth(9), Monika Serke(9), Ulrich Gerigk(9), Yon‐Dschun Ko(9), Richard Riedel(9), Anne M. Schultheis(9)